Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

• Главные авторы: Kevin Bowrin (Автор), Jean-Baptiste Briere (Автор), Pierre Levy (Автор), Aurélie Millier (Автор), Jean Tardu (Автор), Mondher Toumi (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF) imposes a substantial economic burden on the UK healthcare system. Objectives An existing Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban and apixaban, each compared with a...